Drug Profile
Vandefitemcel - SanBio
Alternative Names: Modified bone marrow derived mesenchymal stem cells - SanBio; SB-623Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator SanBio
- Developer SanBio; Sumitomo Pharma; Sumitomo Pharma America
- Class Antidementias; Antiparkinsonians; Mesenchymal stem cell therapies; Neural stem cell therapies; Neuroprotectants; Stem cell therapies
- Mechanism of Action Cell replacements; Nerve growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Traumatic brain injuries
- Phase II Cerebral infarction; Stroke
- Preclinical Dry age-related macular degeneration; Parkinson's disease; Retinitis pigmentosa; Spinal cord injuries
- Research Alzheimer's disease
Most Recent Events
- 01 Mar 2024 Vandefitemcel is still in research for Alzheimer's-disease in USA (SanBio Pipeline, February 2024)
- 01 Mar 2024 Vandefitemcel is still in preclinical development for Dry age-related macular degeneration in USA (SanBio Pipeline, February 2024)
- 01 Mar 2024 Vandefitemcel is still in preclinical development for Parkinson's-disease in USA (Intracerebral, Injection) (SanBio Pipeline, February 2024)